These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11162942)

  • 1. Mechanisms of estrogen action in the cardiovascular system.
    Mendelsohn ME
    J Steroid Biochem Mol Biol; 2000 Nov; 74(5):337-43. PubMed ID: 11162942
    [No Abstract]   [Full Text] [Related]  

  • 2. Estrogen actions in the cardiovascular system.
    Mendelsohn ME
    Climacteric; 2009; 12 Suppl 1():18-21. PubMed ID: 19811235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of estrogen on the vascular system.
    Tostes RC; Nigro D; Fortes ZB; Carvalho MH
    Braz J Med Biol Res; 2003 Sep; 36(9):1143-58. PubMed ID: 12937779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular mechanisms underlying the cardiovascular actions of oestrogens.
    Ling S; Komesaroff P; Sudhir K
    Clin Sci (Lond); 2006 Aug; 111(2):107-18. PubMed ID: 16831130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic and nongenomic effects of estrogen in the vasculature.
    Mendelsohn ME
    Am J Cardiol; 2002 Jul; 90(1A):3F-6F. PubMed ID: 12106632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid receptor coactivator-3 is required for inhibition of neointima formation by estrogen.
    Yuan Y; Liao L; Tulis DA; Xu J
    Circulation; 2002 Jun; 105(22):2653-9. PubMed ID: 12045172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice.
    Iafrati MD; Karas RH; Aronovitz M; Kim S; Sullivan TR; Lubahn DB; O'Donnell TF; Korach KS; Mendelsohn ME
    Nat Med; 1997 May; 3(5):545-8. PubMed ID: 9142124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy?
    Li JM; Brooks G
    Eur Heart J; 1999 Mar; 20(6):406-20. PubMed ID: 10213344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Activation Function-1 of Estrogen Receptor Alpha Prevents Arterial Neointima Development Through a Direct Effect on Smooth Muscle Cells.
    Smirnova NF; Fontaine C; Buscato M; Lupieri A; Vinel A; Valera MC; Guillaume M; Malet N; Foidart JM; Raymond-Letron I; Lenfant F; Gourdy P; Katzenellenbogen BS; Katzenellenbogen JA; Laffargue M; Arnal JF
    Circ Res; 2015 Oct; 117(9):770-8. PubMed ID: 26316608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [1998 Nobel Prize in physiology or medicine. Nitric oxide as a signal molecule in the cardiovascular system].
    Hansson GK; Jörnvall H; Lindahl SG
    Lakartidningen; 1998 Oct; 95(43):4703-8. PubMed ID: 9821753
    [No Abstract]   [Full Text] [Related]  

  • 11. Alteration in endothelial estrogen receptor expression: a potential key of vasculoprotection by estrogens?
    Arnal JF; Bayard F
    Circ Res; 2002 Nov; 91(9):759-60. PubMed ID: 12411388
    [No Abstract]   [Full Text] [Related]  

  • 12. Selective estrogen receptor-alpha agonist provides widespread heart and vascular protection with enhanced endothelial progenitor cell mobilization in the absence of uterotrophic action.
    Bolego C; Rossoni G; Fadini GP; Vegeto E; Pinna C; Albiero M; Boscaro E; Agostini C; Avogaro A; Gaion RM; Cignarella A
    FASEB J; 2010 Jul; 24(7):2262-72. PubMed ID: 20203089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The vascular protective effects of estrogen.
    Farhat MY; Lavigne MC; Ramwell PW
    FASEB J; 1996 Apr; 10(5):615-24. PubMed ID: 8621060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting gene expression to specific cardiovascular cell types in transgenic mice.
    Hunter JJ; Zhu H; Lee KJ; Kubalak S; Chien KR
    Hypertension; 1993 Oct; 22(4):608-17. PubMed ID: 8406667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation.
    Geraldes P; Sirois MG; Tanguay JF
    Circ Res; 2003 Sep; 93(5):399-405. PubMed ID: 12893737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protease-activated receptors in the cardiovascular system.
    Coughlin SR
    Cold Spring Harb Symp Quant Biol; 2002; 67():197-208. PubMed ID: 12858541
    [No Abstract]   [Full Text] [Related]  

  • 17. Direct vascular effects of estrogens and selective estrogen receptor modulators.
    Simoncini T; Genazzani AR
    Curr Opin Obstet Gynecol; 2000 Jun; 12(3):181-7. PubMed ID: 10873118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vascular protection with estrogen. In-vitro and in-vivo effects--mechanisms and clinical implication].
    Barton M; Wright E; Dai-Do D; Yang Z; Espinosa E; Arnet U; Lüscher TF
    Praxis (Bern 1994); 1997 Jan; 86(5):129-37. PubMed ID: 9064730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogens as neuroprotectants against ischemic stroke.
    Alonso de Leciñana M; Egido JA
    Cerebrovasc Dis; 2006; 21 Suppl 2():48-53. PubMed ID: 16651814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology.
    Hirano K
    Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):27-36. PubMed ID: 17095716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.